Because linagliptin treatment resulted in similar GLP-1 elevation between ND and T2D islets (Fig. 2A,B), the reduced efficiency of linagliptin in T2D islets might be attributable to the change of GLP-1 receptor (GLP-1R) expression in the islets. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.